Immunome, Inc.

NasdaqCM IMNM

Immunome, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 88.22%

Immunome, Inc. Gross Profit Margin is 88.22% for the Trailing 12 Months (TTM) ending September 30, 2024, a -4.96% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Immunome, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 92.83%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: IMNM

Immunome, Inc.

CEO	Dr. Clay B. Siegall Ph.D.
IPO Date	Oct. 2, 2020
Location	United States
Headquarters	665 Stockton Drive
Employees	55
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Key trends

Past 5 years